IBRX:NASDAQImmunityBio, Inc. Analysis

ImmunityBio is trading around $7.35, just above its computed support of $6.54 and well below its 52‑week high of $12.43, indicating limited upside in the immediate price action. Technical signals are mixed: the 20‑day SMA (7.76) sits slightly below the 50‑day SMA (7.80), the RSI is neutral at 47, and the MACD histogram is negative, suggesting short‑term bearish momentum. Volatility remains extreme at over 116% (30‑day) and beta exceeds 2, underscoring a highly volatile, market‑sensitive stock.
Fundamentally, the company reports negative earnings, a massive operating loss, and a cash burn that outpaces its cash reserves, while carrying a sizable debt load. The price‑to‑sales multiple of nearly 67 and a forward PE of –367 signal that the market is pricing in significant future growth despite current financial weakness. Recent material news includes an FDA warning letter and multiple emerging securities‑fraud class‑action investigations, which heighten regulatory and legal risk. Nonetheless, analyst targets average $13‑$15, implying a potential upside of over 100% from current levels, and the “strong buy” consensus reflects optimism around its pipeline and partnership assets.